Form 4: Vivani Medical Director Dean Baker Granted Stock Options and Power of Attorney

Dean Baker, a director at Vivani Medical, received stock options and granted a limited power of attorney for SEC filings.

Summary

• Dean Baker, a director of Vivani Medical, Inc., was granted stock options and has provided a limited power of attorney.
• The power of attorney authorizes Adam Mendelsohn, Judy Wong, and Brigid Makes to execute SEC forms on Baker's behalf, including Forms 3, 4, 5, Schedules 13D and 13G, and amendments related to his ownership of Vivani Medical securities.
• Baker received an annual grant of 34,839 common stock options with an exercise price of $1.27 on June 27, 2024.
• The options vest fully on the earlier of the first anniversary of the grant or the next annual meeting of stockholders, contingent upon continued service.

Sentiment

Score: 7

Explanation: The document reflects standard corporate governance practices (stock option grant and power of attorney). It's a neutral event with a slightly positive sentiment due to aligning director interests with shareholders.

Positives

• The grant of stock options aligns Dean Baker's interests with those of the shareholders.
• The power of attorney simplifies SEC filing processes for Dean Baker.

Risks

• The power of attorney relies on the attorneys-in-fact to act in Baker's best interest and in compliance with securities laws.
• The vesting of the stock options is contingent upon continued service, which introduces a risk of forfeiture if Baker leaves the company before the vesting date.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Granting stock options to directors is a common practice to incentivize them and align their interests with shareholders. The power of attorney is a standard legal document to facilitate SEC filings.

Comparison to Industry Standards

• Stock option grants for non-employee directors are a common practice across the pharmaceutical and biotech industries.
• Companies like Amgen, Gilead Sciences, and Biogen routinely grant stock options to their directors as part of their compensation packages.
• The vesting schedules and exercise prices are typically benchmarked against industry standards to ensure competitiveness and alignment with shareholder value.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's performance.
• The power of attorney streamlines administrative processes for SEC compliance.

Key Dates